What is Truemeds?
Truemeds operates as a technology-driven tele-health platform dedicated to democratizing access to affordable medicine across India. The company addresses the critical challenge of rising healthcare costs by utilizing a sophisticated, proprietary matching algorithm that recommends high-value, scientifically equivalent alternatives to prescribed medications. This model not only improves patient outcomes through precise clinical matching but also delivers substantial cost savings, often reaching up to 51% for the end consumer. By integrating tele-consultation services with a streamlined supply chain, Truemeds has positioned itself as a vital intermediary in the digital health ecosystem, effectively bridging the gap between affordability and quality care for a vast, underserved demographic.
How much funding has Truemeds raised?
Truemeds has raised a total of $112M across 3 funding rounds:
Series A
$5M
Series B
$22M
Series C
$85M
Series A (2021): $5M with participation from InfoEdge Ventures, Asha Impact, and Indian Angel Network
Series B (2022): $22M led by Westbridge Capital, InfoEdge Ventures, and Asha Impact
Series C (2025): $85M supported by Westbridge Capital Us Advisors, Accel, Peak XV Partners, and Info Edge Ventures
Key Investors in Truemeds
Westbridge Capital Us Advisors
WestBridge Capital is an investment firm that supports Indian entrepreneurs with purpose-driven capital, focusing on long-term growth and sustainable solutions across sectors including healthtech.
Accel
Accel is a global venture capital firm that partners with exceptional teams from the inception of their ideas through all phases of private company growth, providing essential scaling expertise.
Peak XV Partners
Peak XV Partners is a venture capital firm specializing in providing funding and strategic support to technology companies across Asia, with a strong focus on healthcare innovation.
What's next for Truemeds?
With the successful closure of this major enterprise-level funding, Truemeds is well-positioned to accelerate its market penetration and enhance its technological infrastructure. The strategic capital will likely be deployed to scale its tele-consultation capabilities, expand its geographic footprint, and further refine its algorithmic matching engine to support a broader range of therapeutic categories. As the company transitions from a scaling phase to a more mature market-leader status, the focus will remain on maintaining operational efficiency while driving sustainable growth. Investors are expected to provide continued operational guidance, leveraging their deep expertise in the Indian consumer internet and healthtech sectors to navigate the complexities of the evolving regulatory and competitive landscape.
See full Truemeds company page
